Company ProfilePremium

PainChek Limited

Company Profile Analysis

Ticker: PCK.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
PainChek Limited - Company showcase

Year Founded & Workforce

2010

PainChek Limited logo

PainChek Limited Employee Contacts

3 verified contactsNames, job titles, seniority and locations

View Employee Contacts

PainChek Limited Overview

PainChek is a micro-cap Australian digital-health company. It sells a regulator-cleared, AI-enabled smartphone medical device for assessing pain in people who cannot reliably self-report it, chiefly residents with moderate-to-severe dementia in aged care. The app combines automated facial analysis of pain-related facial action units with structured caregiver observation and a Numerical Rating Scale. It is sold mainly as a per-bed software subscription to residential aged care, home care and disability providers. At 30 June 2026, PainChek had 90,198 implemented licences, A$4.46m of implemented ARR, 1,990 active customer sites and 21.38m cumulative assessments, mainly across Australia/New Zealand and the UK. FDA De Novo clearance in October 2025 made PainChek Adult the first regulated device of its kind in the United States. The company is now trying to convert that access into US revenue through Sabra Health Care REIT and other channels. It remains loss-making (FY2026 net loss A$8.94m) and depends on external funding.


Company's own description (FY2026 Annual Report, Directors' Report). PainChek describes itself as a regulator-cleared, AI-enabled medical device that supports pain assessment for people who cannot reliably self-report their pain, while also enabling assessment of people who can. The financial statements describe its principal activity as the development and commercialisation of mobile medical device applications that provide pain assessment for individuals unable to communicate with their carers. Management characterises FY2026 as the year PainChek began "shifting from building market access to converting that access into implemented recurring revenue."

What the product does. A carer uses a smartphone or tablet to capture a short video of the resident's face. PainChek's facial-analysis AI detects facial action units associated with pain. The carer then completes digital checklists of non-facial pain behaviours, such as vocalisation, movement and behaviour. The app combines both inputs into an overall pain score, which is documented at the point of care and synchronised to a cloud portal and the PainChek Analytics reporting suite. PainChek Universal adds the Numerical Rating Scale (NRS), so the same tool can be used for residents who can self-report and those whose ability fluctuates. In the US the device is cleared as a prescription, adjunctive tool. It is not a stand-alone diagnostic or prognostic tool (FDA DEN240073 classification).

Business model.

Revenue model mix. PainChek is essentially a pure subscription business: about 96% subscription and about 4% services. There is no hardware, licensing-to-third-party or royalty revenue (FY2026 Note 3).

Value-chain position. PainChek sits at the clinical-application layer. It does not own care facilities or devices; customers use their own smartphones and tablets. It relies on cloud hosting and on integrations with clinical/electronic health record platforms, citing about 40 integration partnerships (January 2026 business update). Cost of providing services, A$1.10m in FY2026, comprises customer implementation and training ("Customer Excellence"), cloud hosting and integration fees paid to partners.

Customer types and end-markets.

Independent characterisation. PainChek has a defensible regulatory and clinical moat in a narrow niche, but its revenue base is sub-scale. Five years after reaching 100,000 contracted beds (June 2021), recognised customer revenue is A$3.74m. Average realised revenue per implemented licence is about A$49 per year (A$4.46m ARR ÷ 90,198 licences). The commercial model has historically depended on government funding: a A$5m Australian Government grant in 2019 subsidised early adoption. Converting signed licences into paying, implemented licences has been slower than management signalled. The board acknowledged in the FY2026 Annual Report that conversion "did not meet the Company's expectations in all areas." This led to a reset of reported KPIs in July 2026: signed but unimplemented licences are now reported as "pipeline" rather than contracted ARR, together with a CEO change. The investment case now rests almost entirely on US execution, under a newly installed US-based CEO, against a backdrop of going-concern uncertainty and a A$5.5m convertible note maturing in May 2027.

Strategy

Stated strategy (FY2026 Annual Report)

The Chair's letter frames FY2027 around "a sharper focus on conversion and execution." The company states it has "established the technology, regulatory access and commercial pathways," and that FY2027 is about converting those foundations into measurable commercial outcomes. The five stated FY2027 priorities are:

  1. Implement faster: accelerate conversion of contracted and qualified opportunities into implemented licences and ARR.

  2. Convert the US pipeline: move priority US pilots into deployments, focusing on larger long-term care, skilled nursing and memory-care groups.

  3. Expand existing customers: increase licence implementation and utilisation within accessible customer groups, particularly in the UK.

  4. Retain and grow the core: maintain retention and increase utilisation in ANZ.

  5. Maintain commercial discipline: direct investment to opportunities that can generate implementation, utilisation and recurring revenue, reported against a focused set of measures.

Regional priorities (Annual Report)

  • UK and Ireland: "Existing Customers → Implementation → Recurring Revenue."

  • ANZ: "Retention – Utilisation – Expansion."

  • United States: "Qualified Pipeline – Deployment – Implemented Licences."

  • Canada: initial residential aged-care sales are in place, and the company is exploring additional aged-care and home-care partners.

Commercial model articulation: Market Access → Qualified Pipeline → Implementation → Implemented ARR → Customer Revenue and Receipts. PainChek now prioritises implemented ARR, retention and expansion over contracted licence counts.

Strategic initiatives in the last 24 months

InitiativeDateDescriptionStatus
FDA De Novo pathwaySubmission Dec 2024; final submission 21 Jul 2025; granted 6 Oct 2025First FDA classification for AI pain-assessment software in non-communicative adultsComplete
North American operating baseFY2026Incorporation of PainChek Inc and PainChek Canada; US Head of BD hired (May 2025); US staffComplete; continuing
Sabra Health Care REIT MSA14 Apr 2026Owner-funded licences across up to 329 facilities / 20,000 beds; Sabra required to introduce PainChek to current and future operatorsFirst two 3-year contracts (Traditions) signed June 2026
RTM reimbursement ("PainChek Plus")Jan 2026Legal opinion that PainChek qualifies for RTM; PMPM model; planned launch at HIMSS March 2026No revenue disclosed
CMS-specific CPT codeTargeted by Apr 2026Application for a PainChek-specific codeOutcome not disclosed in sources reviewed
CMMI home-health programs (ACCESS, TEMPO)Jan 2026Positioning for CMS Innovation Center-funded modelsExploratory
Mayo Clinic PlatformFY2026"Mayo Clinic Platform Accelerate" participation (Annual Report); qualification stage with Mayo Clinic Platform Solutions Studio (June 2026 4C)In qualification
Silverado memory-care pilotJul 2026Initial pilot with a top-tier US memory-care operatorPilot
Infant channel pivotJun 2026 quarterHealthcare-professional and pharmacy recommendation channel replaces broad direct-to-consumer; SA pharmacy pilot from 1 Jul 2026Pilot
Platform Dashboard release8 Jul 2026Workflow, compliance and follow-up visibility for aged care and home careRolled out globally
KPI redefinitionJul 2026Unimplemented contracts reclassified as pipeline; focus on implemented ARRAdopted
Leadership refreshMay–Sep 2026New Chair, new US-based CEO, two long-serving directors departedComplete
ROI evidence programJun 2026Casson Consulting UK ROI study: about 10p per bed per day, about 3.3% of the benefitsPublished
European validations2,026Portuguese usability study; German validation; Spanish (Granada) infant scopingIn progress
Cost focusFY2026–FY2027R&D refocused on core product; R&D payments down A$72k quarter on quarter in the June 2026 quarterOngoing

Medium-term financial targets and guidance

PainChek has not issued quantitative revenue, ARR, EBITDA or cash-flow-breakeven guidance in the sources reviewed. Its targets are qualitative ("delivering growth in FY2027"). Market-sizing claims by management include:

  • US aged care: US$150m per year (1.5m people with dementia).

  • US home care: US$300m per year.

  • US RTM market: US$3.0bn by 2030 at a 17.2% CAGR, citing Data Bridge Market Research.

The company also claims US patent protection aligned to the RTM claims process "until 2038" (January 2026 business update). Previous timing guidance proved optimistic: FDA clearance was expected by mid-2024 (FNArena, September 2023), then the first half of calendar 2025 (H1 FY2025 report), then mid-to-late September 2025, and was received in October 2025.

ESG and sustainability commitments: none disclosed beyond information-security certifications (ISO 27001, SOC 2) and a Diversity and Inclusion policy (October 2024).

Products & Services

Adult segments (ANZ, UK, North America)

PainChek Adult App (flagship)

Description: A smartphone/tablet medical device app. AI-driven automated facial recognition and analysis identifies facial action units indicative of pain, and the carer adds structured observations of non-facial pain domains. Together these produce a pain-intensity score. Functions include pain assessment, pain monitoring, patient profiling and data synchronisation to a web portal (Atee, Hoti, Hughes et al., Frontiers in Aging Neuroscience, 2018).

Key capabilities: An assessment takes about three seconds of video capture (Stockhead, 2021). It works offline with later sync, records assessment history and trends, and documents for compliance and funding claims.

Regulatory status: Cleared in Australia (ARTG 302794), New Zealand, Canada, Singapore, Malaysia, the UK, the EU and the US. The US clearance is FDA De Novo DEN240073, granted 6 October 2025: Class II, prescription-only, adjunctive use, for conscious adults unable to communicate pain.

Target customer: Residential aged care, memory care, skilled nursing, home care and disability providers caring for people with moderate-to-severe dementia or other communication impairment.

Launch / latest version: First regulatory clearance 2017; major dashboard release 8 July 2026.

Pricing (disclosed): - UK: about 10p per bed per day, or about £3,650 per year for a 100-bed group (Casson Consulting / PainChek, June 2026).

  • US core SaaS: "US$50+ per bed per annum" (January 2026 business update).

  • Sabra MSA: US$55–75 per licence per annum, with lower pricing for longer terms or research participation (June 2026 4C).

PainChek Universal

Description: Combines the PainChek AI tool with the Numerical Rating Scale. Clinicians can assess people who can self-report, people who cannot, and those whose ability fluctuates, all in one app.

Launch: March 2021. CE-mark approval for the Universal version is referenced by Biotech Daily (2021).

Target customer: The same aged-care customers, extended to cognitively intact or fluctuating residents.

Pricing: Bundled within the subscription; separate pricing not disclosed.

PainChek Analytics

Description: A reporting suite and portal giving real-time dashboards and reports from frontline nurses to executives and boards. It covers pain trends, assessment compliance, follow-up gaps and treatment-effect monitoring.

Target customer: Clinical managers, quality leads and provider executives.

Pricing: Included in the subscription; not separately disclosed.

Adult Dashboard enhancement (July 2026 release)

Description: A redesigned in-app dashboard with real-time resident pain status. Adds two new views ("Follow-up Assessments" and "Routine Assessments") and configurable reassessment workflows tied to pain severity and risk. Flags positive pain assessments not followed up within policy timeframes. Also adds improved search and filtering, faster navigation, and online/offline status visibility.

Rollout: Global from 8 July 2026. Enabled by default for new customers; existing customers activate it after training.

Commercial significance: Management says the release contributed to new licence opportunities. Named endorsements came from Lutheran Services (Australia) and Perley Health (Canada).

PainChek Plus (US reimbursed model)

Description: A device-service agreement with qualified healthcare professionals (physiotherapists, physicians, occupational therapists, GPs) serving skilled nursing facilities. These professionals use PainChek to support billing of Remote Therapeutic Monitoring codes for musculoskeletal pain: CPT 98975 setup, 98985/98977 data capture, 98979/98980/98981 treatment management.

Pricing structures proposed (January 2026 deck): Model 1 is a fixed per-member-per-month (PMPM) fee. Model 2 is a lower PMPM plus revenue share. Management cites RTM claims of about US$150 per resident per month to providers.

Status: Planned launch at HIMSS (Las Vegas), March 2026. No revenue or contracts disclosed to date. The company also said it was pursuing a PainChek-specific CPT code with CMS by April 2026; the outcome was not disclosed in the sources reviewed.

Integration connectors

  • About 40 integration partnerships with clinical systems globally (January 2026). Named partners include PointClickCare, Eldermark and Yardi (North America); Telstra Health (Australia); Leecare Solutions and Person Centred Software (UK); and TrakCare (hospital pilot, Edinburgh).

Purpose: PainChek runs inside clinical records already used by care teams, lowering implementation friction.

Implementation and training services ("Customer Excellence")

Description: Onboarding, training (including online learning and training registration), support and release management.

FY2026 revenue: A$138,352 (training and services).

Language variants

  • PainChek-PT (Portuguese): usability study published June 2026.

  • German-language version: validated by the University of Applied Sciences and Arts Bielefeld; manuscript in preparation.

  • A US validation in ethnically diverse dementia cohorts (African American, Hispanic/Latino, Asian) was being finalised for peer-reviewed publication (June 2026 4C).

Infant segment

PainChek Infant App

Description: A clinically validated app that detects six facial action units indicative of pain in infants aged 1 to 12 months (company boilerplate, July 2026).

Origin: The Murdoch Children's Research Institute "PainFaces" study, partnered July 2019.

Target customer: Parents, recommended by healthcare professionals and pharmacies.

Launch: April 2025 in Australia, direct to parents; marketing live from mid-2025.

Strategy change (June 2026 quarter): Shifted from broad direct-to-consumer marketing to healthcare-professional and pharmacy channels. Proposed added features are comforting strategies, a head-to-toe assessment, red-flag guidance and reassessment reminders.

Pilot: From 1 July 2026, 10–12 community pharmacies in South Australia, with a national pharmacy network (unnamed). The University of Granada is scoping a study on infant analgesic monitoring via pharmacies.

Pricing: Not publicly disclosed.

Revenue: A$293 in FY2026 (FY2025: A$935).

Addressable market (company claim): About A$15bn (October 2025 announcement). About 400m births per year, of which 150m are to first-time parents (Biotech Daily, October 2025).

  • The FY2026 STI scorecard records that Infant App objectives were not achieved.

Financial Narrative

Income statement

Sources and notes

Revenue: FY2022 and FY2024 from StockAnalysis (aggregator). FY2023 is A$1.95m per FNArena's summary of the FY2023 preliminary report. FY2025 and FY2026 are audited customer revenue. FY2025 total revenue including interest is A$3,362,427.

R&D: FY2022 and FY2023 are "research expense" per the FY2023 preliminary report. FY2024 is from StockAnalysis (aggregator). FY2025 and FY2026 are audited.

Net losses: FY2022–FY2024 from the FY2026 remuneration report five-year table.

EBITDA definition: loss before tax, plus note interest, less interest income, plus depreciation. It includes R&D tax incentive income.

Operating income definition: customer revenue less all operating expenses, excluding other income.

Gross profit definition: customer revenue less cost of providing services. Aggregators use broader cost-of-revenue definitions and report much lower gross profit (StockAnalysis: FY2025 A$1.00m).

Revenue CAGR

The 3-year revenue CAGR from FY2023 to FY2026 is about 24.3%.

Margins

Management describes the business as having "80%+ gross margins" (January 2026 business update). That likely excludes implementation labour. The audited cost-of-service line implies about 70–71%.

Balance sheet

Sources and notes

Cash: FY2022–FY2024 from TipRanks (aggregator); FY2023 is also confirmed at A$2.51m by FNArena. FY2025 and FY2026 are audited.

FY2024 equity and accumulated losses: from the 1 July 2024 opening balances in the FY2025 statement of changes in equity.

Convertible notes: face value A$5.5m. Equity component of A$1.39m recognised in reserves.

R&D refund: the A$1.12m receivable is included in FY2026 receivables and was received on 22 July 2026.

Working capital: the going-concern note gives net current liabilities of A$63,478 (FY2025: A$1,132,464).

Unrecognised deferred tax assets: A$9.46m on tax losses at 25%. None are recognised on balance sheet.

Cash flow

Sources and notes

Free cash flow: FY2022–FY2024 from StockAnalysis (aggregator).

Financing cash flow: FY2022–FY2024 from TipRanks (aggregator).

FY2023 receipts: FNArena.

R&D refund timing: FY2026 operating cash flow received no R&D refund (FY2025: A$1.412m). The FY2025-year refund slipped into July 2026 (FY2027), which depresses FY2026 operating cash flow by about A$1.1m relative to FY2025.

Ratios

Why several ratios are n/a

  • ROE and debt to equity: equity is negative in FY2025 and FY2026.

  • ROIC: invested capital is negative.

  • Net debt to EBITDA: the company is in a net cash position with negative EBITDA.

  • Interest coverage: EBIT is negative.

  • The cash conversion cycle is not meaningful for an inventory-free subscription business. Customers prepay part of their subscriptions: contract liabilities were A$1.33m, about 36% of revenue.

Trend commentary

Revenue growth is decelerating sharply. Growth slowed from 97% (FY2023) to 37% (FY2024), 26% (FY2025) and 11% (FY2026), even as implemented licences grew 27.9% in FY2026. The gap reflects several factors:

  • Activations clustered late in the year, as shown by a 27% rise in June-quarter receipts.

  • Pricing mix: UK and pilot licences at lower rates, and US Sabra pricing at US$55–75.

  • Implemented ARR (A$4.46m) running ahead of recognised revenue.

The H1 FY2026 result showed customer revenue up only 5% to A$1.734m. That was the key inflection that preceded the board and CEO changes.

Cost base inflection. Total operating expenses rose from A$12.47m to A$13.66m in FY2026 (+9.5%):

  • Marketing and business development rose 25% to A$5.06m, for US/Canada sales set-up.

  • Corporate and administration rose 15% to A$3.70m, driven by Chair/CEO recruitment, US/Canada entity set-up, and higher legal, ASX and registry costs.

  • R&D fell 12% to A$3.32m after FDA clearance, as the company focused on the core product.

Losses. The net loss widened 16% to A$8.94m, the largest in five years after FY2024's A$8.31m. Two factors contributed: R&D tax incentive income fell from A$1.41m to A$1.12m, and a new A$0.20m note-interest charge was added. The interest charge accrues at a 54.7% effective rate under compound-instrument accounting; cash interest is 12%.

Balance sheet. Equity has been negative since FY2025. Cash of A$5.99m at 30 June 2026 was funded almost entirely by capital raised during FY2026: A$13.6m net, made up of a A$7.5m placement, A$1.09m of option exercises and the A$5.5m notes. The June 2026 Appendix 4C reported about 3.3 quarters of funding at the June-quarter burn rate (A$1.79m), before the A$1.12m R&D refund.

Funding dependency. Over FY2022–FY2026, cumulative free cash flow was about -A$36.5m and cumulative financing inflows about A$31.1m (partly aggregator data). PainChek has never generated positive operating cash flow.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContents

Adult ANZ

PainChek Adult / Universal app, Analytics, implementation and training sold to aged-care, home-care and disability providers in Australia and New Zealand

Adult UK

Same products in the United Kingdom (including Scotland) via PainChek UK Limited

Adult North America

Same products in the US and Canada (PainChek Inc, PainChek Canada Limited). FDA-cleared PainChek Adult; Sabra MSA; RTM model.

Infant ANZ

PainChek Infant app (direct-to-parent, then healthcare-professional/pharmacy channel)

Revenue by Segment

SegmentFY2024FY2025FY2026

Adult ANZ revenue (AUD Mn)

—2.1642.284

Adult UK revenue (AUD Mn)

—1.1931.415

Adult North America revenue (AUD Mn)

—0.0000.044

Infant ANZ revenue (AUD Mn)

—0.0010.000

Total customer revenue (AUD Mn)

2.673.3583.742

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (FY2025–FY2026)

SegmentFY2025FY2026

Adult ANZ contribution (AUD Mn)

-0.0440.612

Adult UK contribution (AUD Mn)

-0.978-0.844

Adult North America contribution (AUD Mn)

-0.058-1.530

Infant ANZ contribution (AUD Mn)

-0.399-0.503

Total segment contribution (AUD Mn)

-1.479-2.264

Segment Revenue

SegmentFY2025 contribution margin (%)FY2026 contribution margin (%)FY2026 revenue YoY (%)FY2025 share of revenue (%)FY2026 share of revenue (%)

Adult ANZ

-2.126.85.664.461.0

Adult UK

-82.0-59.618.635.537.8

Adult North America

n/m

n/m

n/m

0.01.2

Infant ANZ

n/m

n/m

-68.70.00.0

Segment Overview — Adult ANZ

SegmentRevenueCost of providing servicesMarketing and BDContribution

Adult ANZ

2,283,670(406,016)(1,265,753)611,901

Adult UK

1,414,524(556,168)(1,701,860)(843,504)

Adult North America

43,584(140,717)(1,433,033)(1,530,166)

Infant ANZ

293(32)(502,910)(502,649)

Total

3,742,071(1,102,933)(4,903,556)(2,264,418)

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Customer revenue (AUD Mn)

0.991.952.673.363.74

Revenue growth (%)

325.196.736.625.811.4

Subscription revenue (AUD Mn)

———3.143.60

Training and services revenue (AUD Mn)

———0.220.14

R&D tax incentive and grants, other income (AUD Mn)

———1.441.15

Cost of providing services (AUD Mn)

———0.971.10

Gross profit, company basis (AUD Mn)

———2.392.64

Research and development expense (AUD Mn)

2.353.494.573.783.32

Marketing and business development expense (AUD Mn)

———4.045.06

Corporate and administration expense (AUD Mn)

2.783.36—3.223.70

Share-based payments expense (AUD Mn)

0.55——0.470.47

Operating income, excluding other income (AUD Mn)

———-9.12-9.92

EBITDA (AUD Mn)

———-7.66-8.75

Pre-tax income (AUD Mn)

-5.72-7.57-8.31-7.67-8.94

Net income (AUD Mn)

-5.72-7.57-8.31-7.67-8.94

EPS basic, as reported (A$ cents)

-5.1-5.9-5.7-0.44-4.3

EPS diluted, as reported (A$ cents)

-5.1-5.9-5.7-0.44-4.3

Dividends per share (A$ cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2023FY2024FY2025FY2026

Revenue CAGR from FY2022 (%)

97.064.250.639.4

Margin Analysis (%) (FY2022–FY2026)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin, company basis (%)

———71.270.5

Operating margin, excluding other income (%)

———-271.6-265.0

EBITDA margin (%)

———-228.1-233.8

Net margin (%)

-577.8-388.2-311.2-228.4-238.8

R&D as share of revenue (%)

237.4179.0171.2112.588.8

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD Mn)

6.142.513.561.625.99

Trade and other receivables (AUD Mn)

———0.511.61

Total assets (AUD Mn)

———2.157.63

Short-term debt, convertible notes at carrying value (AUD Mn)

00004.25

Long-term debt (AUD Mn)

00000

Total debt (AUD Mn)

00004.25

Net debt, negative means net cash (AUD Mn)

-6.14-2.51-3.56-1.62-1.74

Contract liabilities, deferred revenue (AUD Mn)

———1.071.33

Total liabilities (AUD Mn)

———3.267.67

Total equity (AUD Mn)

——1.29-1.11-0.04

Goodwill and intangibles (AUD Mn)

———00

Working capital (AUD Mn)

———-1.13-0.06

Accumulated losses (AUD Mn)

——-56.89-64.56-73.50

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers (AUD Mn)

—2.24—3.524.00

Operating cash flow (AUD Mn)

———-6.75-9.24

Capex (AUD Mn)

———0.010.01

Free cash flow (AUD Mn)

-7.02-6.34-7.16-6.77-9.25

Financing cash flow (AUD Mn)

1.752.708.214.8213.64

Equity raised (AUD Mn)

———4.828.14

Convertible notes raised (AUD Mn)

00005.50

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2025FY2026

ROA, on average assets (%)

—-182.7

Current ratio (x)

0.650.99

Asset turnover, on average assets (x)

—0.77

Days sales outstanding, trade receivables (days)

4837

Revenue by Region

RegionFY2024FY2025FY2026

Australia revenue (AUD Mn)

—2.1372.182

United Kingdom revenue (AUD Mn)

—1.1931.415

Other countries revenue (AUD Mn)

—0.0270.146

Total revenue (AUD Mn)

2.673.3583.742

Revenue by Region (%)

Region (%)FY2026 YoY growth (%)FY2026 share (%)

Australia

2.158.3

United Kingdom

18.637.8

Other countries (NZ, US, Canada)

432.13.9

Segment Overview — Adult

SegmentAustraliaNew ZealandUnited KingdomUS/Canada

Adult (AUD Mn)

2.1820.1021.4150.044

Infant (AUD Mn)

0.0000.0000.0000.000

Operating Metrics (number) and Revenue by Region

RegionMar-2026Jun-2026

ANZ implemented licences (number)

53,90455,246

UK implemented licences (number)

30,08233,470

North America implemented licences (number)

1,2141,482

Total implemented licences (number)

85,20090,198

ANZ implemented ARR (AUD Mn)

2.472.54

UK implemented ARR (AUD Mn)

1.681.85

North America implemented ARR (AUD Mn)

0.060.07

Total implemented ARR (AUD Mn)

4.214.46

Revenue by Region and Operating Metrics (number)

MetricDec-2024Mar-2025Jun-2025Sep-2025Dec-2025Mar-2026Jun-2026

Implemented ARR (AUD Mn)

3.33.43.583.53.74.214.46

Contracted ARR, when fully implemented (AUD Mn)

4.84.95.55.65.65.9—

Implemented licences (number)

68,45871,08870,53971,75175,59085,20090,198

Share Price and Share Count (m)

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.280.250.270.450.10

Shares on issue at 30 June, post-consolidation basis (m)

——163.6184.2209.0

Market capitalisation at 30 June (AUD Mn)

——44.282.920.9

Performance Window Details

Performance windowReturn (%)Basis

1-year (30 Jun 2025 – 30 Jun 2026)

-77.8

A$0.45 to A$0.10

3-year (30 Jun 2023 – 30 Jun 2026)

-60.0

A$0.25 to A$0.10

4-year (30 Jun 2022 – 30 Jun 2026)

-64.3

A$0.28 to A$0.10

From post-FDA peak (10 Oct 2025, about A$0.80 adjusted)

About -87

Biotech Daily, Oct 2025; adjusted from A$0.08 pre-consolidation

Valuation Snapshot

MultipleValueBasis

Market capitalisation

About A$20.9m

209.0m shares × A$0.10

Enterprise value

About A$19.2m (carrying debt) to A$20.4m (face value)

Plus notes A$4.25m carrying / A$5.5m face, less cash A$5.99m (30 June 2026)

EV / Sales (FY2026)

About 5.1–5.5x

A$3.74m customer revenue

EV / Implemented ARR

About 4.3–4.6x

A$4.46m

P/E

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

P/B

n/m

Negative book equity (-A$0.04m)

Peer multiples

Not publicly available for comparable direct peers

No listed direct competitors

Capital Markets

ItemDetail

Dividend history

Never paid; no dividends or capital returns in the last 5 years. No franking credits available.

Dividend policy

None; loss-making

Buybacks

None authorised or executed

Credit ratings (Moody's / S&P / Fitch)

Not rated

Bank facilities

None (Appendix 4C, section 7: no loan or standby facilities)

Capital Markets Data

MetricFY2026FY2027FY2028

Convertible notes face value maturing (AUD Mn)

05.50

Share Price & Returns

DateInstrumentPriceProceeds

Dec 2024 – Mar 2025

Entitlement offer and placement

A$0.025 pre-consolidation (A$0.25 adjusted)

About A$5.12m gross

Jul–Aug 2025

Placement (22.06m post-consolidation shares)

A$0.034 pre-consolidation (A$0.34 adjusted)

A$7.5m gross

FY2026

Option exercises (2.22m shares)

A$0.50 adjusted

A$1.09m

May 2026

Convertible notes

Conversion at A$0.195

A$5.5m

Analyst Conclusions

Management guidance

No quantitative guidance. Management's qualitative outlook for FY2027 (Annual Report and June 2026 4C) has four parts:

  • Accelerate revenue growth.

  • Convert qualified opportunities into implemented licences.

  • Expand utilisation within existing customers.

  • Execute partnerships, chiefly Sabra, that can scale market access.

These priorities are to be pursued "with a strengthened balance sheet." Management also said June-quarter staff savings are not indicative of the future cost base.

Consensus growth expectations

No reliable consensus exists (see 21.3). An analyst reference point, not a forecast: entering FY2027 with A$4.46m of implemented ARR, FY2027 recognised revenue should exceed FY2026's A$3.74m on run-rate alone. Implemented ARR exceeds FY2026 revenue by about 19%.

Bull case (grounded in data)

  1. The Sabra template scales. Converting even half of Sabra's up to 20,000 beds at US$55–75 adds roughly US$0.55–0.75m of ARR. Replicating the owner-funded model with other healthcare REITs could multiply North American ARR (A$0.07m today) several-fold with limited sales cost.

  2. A US-specialist leadership team fixes conversion. Holzberger's Nuance and GE Healthcare commercial background is the right profile for US enterprise selling. With ANZ already contribution-positive (A$0.61m) and the UK growing about 19%, US traction plus RTM reimbursement could re-rate a stock trading at about 4–5x EV/ARR.

  3. Embedded clinical product with a moat. Retention of 85–93%, 22m+ assessments, FDA De Novo first-mover status and about 40 EHR integrations make PainChek a logical acquisition target for an EHR or aged-care platform. The roughly A$20m equity value is small relative to the regulatory and data assets.

Bear case (grounded in data)

  1. Refinancing overhang. At 30 June 2026 the company had A$5.99m cash, an operating burn of A$1.79m in the June quarter, and A$5.5m of notes due in May 2027 with conversion about 95% above the current price. A dilutive equity raise or note restructuring in the next 6–9 months looks highly probable. The auditor's going-concern emphasis of matter underlines this.

  2. Conversion has repeatedly disappointed. Revenue growth fell from 97% to 11% over three years. Contracted ARR (A$5.9m) was never realised before the KPI was abandoned. US revenue was only A$44k in the first year after FDA clearance despite A$1.43m of segment marketing spend.

  3. Low price point and free substitutes cap the economics. Implemented ARR of about A$49 per licence, competing with free scales (Abbey, PAINAD), means even large licence wins produce small revenue. The RTM model (PainChek Plus) and the CMS code remain unproven, with no disclosed revenue.

Key catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorableWhat to watch
By late Oct 2026September 2026 quarter 4C (first under new CEO)Implemented ARR (above A$4.46m?), North American licences, receipts, cash burn, cash balance including the A$1.12m refund
4 Nov 2026AGMCEO strategy; votes on Chair/NED equity and remuneration; any capital-management resolutions (note options, placement capacity)
Q2 FY2027Sabra network conversionsNumber of additional operators and facilities signed and implemented
Q2–Q3 FY2027RTM / PainChek PlusFirst reimbursed contracts; CMS CPT-code status
Q2–Q3 FY2027Mayo Clinic Platform qualification; Silverado pilot conversionProgression to commercial terms
Late Feb 2027H1 FY2027 resultsRevenue growth re-acceleration versus H1 FY2026's +5%
Before May 2027Convertible note maturity (A$5.5m)Refinancing, redemption or restructuring; equity raise size and price
FY2027Infant pharmacy pilot readoutGo/no-go on broader infant investment
FY2027Board renewalAdditional NED appointments; creation of audit and remuneration committees
FY2027Peer-reviewed US diverse-cohort publication; German validationEvidence for US and EU adoption

Concluding analyst verdict

PainChek has built something genuinely rare: a clinically validated, multi-jurisdiction-cleared AI medical device that addresses a real and under-served problem. It has an FDA De Novo classification that no competitor holds, a customer base that rarely leaves, and usage that is compounding faster than revenue. Assessments grew 76% in FY2026; revenue grew 11%. The business is not short of product-market validation. It is short of commercial throughput and capital.

The FY2026 accounts are sobering. Revenue of A$3.74m against an operating cost base of A$13.7m, negative equity, and a going-concern emphasis of matter mean PainChek remains a funding-dependent company ten years after listing. The board's own language is unusually candid about conversion falling short. It drove an overhaul in mid-2026: a new Chair, a US-based CEO, the departure of two founding-era directors and the abandonment of the "contracted ARR" metric in favour of implemented ARR. Investors should welcome the more honest scorecard. It also confirms that earlier headline metrics overstated near-term revenue.

The investment question for the next 12 months is binary. Either the new leadership converts US access into a visible, repeatable revenue engine fast enough to refinance the May 2027 notes on acceptable terms, or the company raises equity from a position of weakness. The Sabra owner-funded model is the most promising proof point, and Holzberger's profile fits the task. However, the September and December 2026 quarterlies must show North American licences moving from the low thousands toward the tens of thousands.

At about A$20m of market value and about 4–5x implemented ARR, the equity prices in significant execution and dilution risk. That pricing creates asymmetric upside if US conversion and RTM materialise, or if a strategic acquirer values the regulatory and data assets. Until conversion is demonstrated and the balance sheet is repaired, PainChek is a speculative, catalyst-driven holding. Position sizing should assume a further capital raise.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground / educationFY2026 total remuneration

Karen Holzberger

Chief Executive Officer (US-based)

From 17/18 Aug 2026 (date differs between July announcement and Annual Report)

26 years in healthcare leadership. Most recently President and CEO of SpinTech MRI (FDA-cleared STAGE MRI software). Previously SVP and GM, Nuance Healthcare Diagnostic Division (Nuance was acquired by Microsoft for about US$19.7bn in 2022). Before that, VP and GM, GE Healthcare Global Radiology Workflow. B.S. Mechanical Engineering, Stevens Institute of Technology. Age not disclosed.

Not applicable for FY2026. Package: US$387,000 per year fixed, plus STI/LTI eligibility (terms to be set by the board), 3-month notice.

Andrew (Andy) Hoggan

Chief Operating Officer (Interim CEO 6 Jul – 17 Aug 2026)

Start date not disclosed

—

Not a disclosed KMP

Iain McAdam

Chief Financial Officer

Since 22 Mar 2021

Not detailed in sources reviewed

A$323,767 (base A$245,211; cash bonus A$18,897; options A$21,403; super A$31,122; long-service leave A$7,134)

Prof. Jeff Hughes

Chief Scientific Officer

Co-founder (Curtin University)

Pharmacist-academic; co-inventor of ePAT

Not disclosed (not KMP)

Prof. Kreshnik Hoti

—

Co-founder researcher

Co-inventor; lead author of 2026 Age and Ageing and Frontiers papers

—

Tandeep Gill

General Manager and Head of Business Development, UK

———

David Allsopp

Head of Business Development, ANZ

———

Natalie Climo

Company Secretary (Boardroom)

Since 19 Jan 2024

LLB, GDLP; 15 years' corporate experience

Paid via company secretarial fees (A$73,868 in FY2026)

Philip Daffas (former)

CEO and Managing Director

30 Sep 2016 – 6 Jul 2026 (employment ended 6 Oct 2026)

BSc, Dip EEng, MBA, GAICD. About 30 years in diagnostics (Roche/Boehringer Mannheim, UK and Germany).

A$449,450 (base A$244,099; STI A$18,000 of a possible A$150,000; performance rights A$136,455; super A$28,417; long-service leave A$22,479)

“—” = not publicly disclosed.

Board of Directors

NameRoleAppointedIndependence (analyst view)BackgroundFY2026 total remuneration (AUD)

Lil Bianchi

Non-Executive Chair

25 May 2026

Independent

BSc(Econ), MSc Computer Science, GAICD. Chair of 4DMedical (ASX: 4DX); NED of Qscan Radiology Group and Murrumbidgee Irrigation.

16,667

John Murray

Non-Executive Director (Chair 2016–May 2026)

30 Sep 2016

Independence weakened by 10-year tenure as former Chair

LLB (Hons), CA, MAICD. Co-founder of Technology Venture Partners. Director of Seeing Machines (AIM). Former Viator director.

137,494

Adam Davey

Non-Executive Director

30 Sep 2014 (pre-RTO MinQuest board)

Questionable: Director of Wealth Management at Canaccord Genuity Patersons, a broker; 12-year tenure

Capital markets, ASX listings, M&A. NED of The Agency Group Australia.

70,413

Cynthia Payne

Non-Executive Director

30 Mar 2022

Independent

MBA, B.App.Sci (Nursing). Founder of Anchor Impact Group. Aged-care governance credentials.

70,413

Major Shareholders

HolderShares% of 209.0m sharesPerformance rights

Philip Daffas (former CEO)

3,114,2261.491,276,358

John Murray

1,854,4600.8996,852

Adam Davey

1,606,6580.7748,426

Ross Harricks (departed)

1,180,7270.5648,426

Cynthia Payne

369,5880.1848,426

Lil Bianchi

00.00

0 (to be approved)

Iain McAdam (CFO)

54,1760.03

400,000 options

Total directors at 30 June 2026

8,125,6593.891,518,488

Current board only (Bianchi, Murray, Davey, Payne)

3,830,7061.83—

Competitive Landscape

Key Competitors

Competitor / substituteCategorySegment overlapRelative positioning

Abbey Pain Scale

Observational pain scale (free)

Adult ANZ/UK

Australian standard before PainChek. Dr Jennifer Abbey is now a PainChek advisor. Zero cost, but subjective.

PAINAD (Pain Assessment in Advanced Dementia)

Observational scale (free)

Adult US/global

Widely used in US nursing homes; PainChek must displace it inside EHR workflows

PACSLAC-II

Observational checklist

Adult (Canada/global)

Comprehensive but time-consuming

DOLOPLUS-2

Observational scale

Adult (Europe)

Incumbent in parts of continental Europe

NOPAIN (Non-Communicative Patient's Pain Assessment Instrument)

Observational scale

Adult

Legacy instrument

FLACC / NIPS infant scales

Observational scales

Infant

Clinical standard for infant pain; free

PointClickCare

Long-term-care EHR (private)

Adult North America

Integration partner. Hosts scales natively, so it could build a competing feature.

MatrixCare

Long-term-care EHR

Adult US

Embeds standard assessments; no disclosed PainChek integration

Person Centred Software

UK digital care records (private)

Adult UK

Integration partner and channel; also a potential substitute

SafelyYou

AI video monitoring, US memory care (private)

Adult US (budget competition)

Competes for memory-care technology spend and AI-monitoring mindshare

Hinge Health

Digital MSK / RTM (listed in the US)

US reimbursement model

Established RTM biller; competes for MSK RTM economics, not dementia pain assessment

Sword Health

Digital MSK / RTM (private)

US reimbursement model

As above

Competitor Detail

MetricPainChek (FY2026)

Revenue

A$3.74m

Revenue growth

11.4%

Gross margin

70.5% (company basis)

Net margin

-238.8%

R&D intensity

88.8% of revenue

Regulatory status for pain assessment

FDA De Novo, TGA, CE/UKCA, Health Canada and others

Recent Developments

The June 2026 quarter noted lower staff payments from "staff changes, short-term vacancies and timing," which management said is not indicative of the future cost base.

Company Snapshot

2010

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Unique US regulatory position. FDA De Novo DEN240073 (granted 6 October 2025) created a new Class II device type, and PainChek Adult is described as the first and only such regulated device in the US.
  • Multi-jurisdiction clearance. Cleared in Australia (ARTG 302794), New Zealand, Canada, Singapore, Malaysia, the UK, the EU and the US.
  • Sticky customer base. Retention is 85% globally and 93% in Australia (FY2026). 59% of implemented contracts are 3 or more years old (January 2026). Net licence retention was 106% (July 2025).
  • Recurring revenue quality. Subscriptions are 96.3% of FY2026 customer revenue. Contract liabilities of A$1.33m show customers prepay.
  • Growing clinical utilisation. Cumulative assessments rose 75.6% to 21.38m in FY2026 and passed 22m by September 2026, showing the product is embedded in workflows.
  • Peer-reviewed evidence and ROI case. Publications in the Journal of Alzheimer's Disease, BMC Geriatrics, Age and Ageing (2026) and Frontiers (2026). The Casson UK ROI study (June 2026) put cost at about 10p per bed per day.
  • ANZ unit economics proven. The Adult ANZ segment delivered a positive A$0.61m contribution (26.8% margin) in FY2026.

Weaknesses

  • Sub-scale and slowing revenue. FY2026 customer revenue was A$3.74m, with growth slowing from 97% (FY2023) to 11.4% (FY2026). H1 FY2026 growth was only 5%.
  • Persistent heavy losses. Net losses were A$5.7–8.9m a year over FY2022–FY2026, with accumulated losses of A$73.5m at 30 June 2026.
  • Negative equity and going-concern uncertainty. Equity was -A$0.04m at 30 June 2026 (FY2025: -A$1.11m). The FY2026 audit report includes a going-concern emphasis of matter.
  • Poor conversion of signed licences. Contracted licences peaked at 118,577 (March 2026) against 90,198 implemented (June 2026). The board conceded conversion "did not meet the Company's expectations," and the CEO's FY2026 financial STI paid out at zero.
  • Thin governance infrastructure. There are no audit or remuneration committees; the full four-person board performs these roles. One director is affiliated with a stockbroking firm.
  • Low realised pricing. Implemented ARR per licence is about A$49 per year, and Sabra pricing is US$55–75, limiting revenue per win.
  • Track record of missed timelines. FDA clearance was guided for mid-2024, then the first half of 2025, then September 2025, and was received in October 2025. Infant and European objectives were missed in FY2026.

Opportunities

  • US long-term-care penetration. Management estimates about US$150m per year in aged care and US$300m in home care. Current North American ARR is A$0.07m.
  • Sabra network roll-out. Up to 20,000 beds and 329 facilities. Full penetration at US$55–75 implies roughly US$1.1–1.5m of ARR (analyst arithmetic), about 25–35% of current group ARR.
  • Other healthcare REITs and institutional owners, using the Sabra template (June 2026 4C).
  • RTM reimbursement ("PainChek Plus") in a US$3.0bn-by-2030 RTM market (third-party estimate cited by company), plus a possible CMS-specific code.
  • UK expansion within accessible groups. Licences grew 11.3% in the June 2026 quarter, and Methodist Homes activated about 3,000 licences.
  • Infant via pharmacy and healthcare-professional channels. A South Australian pilot started 1 July 2026; Granada research is being scoped.
  • European entry via validated Portuguese and German versions, building on existing CE-mark clearance.

Threats

  • Funding and refinancing. A$5.5m of notes mature around May 2027. The A$0.195 conversion price is about twice the current share price, making conversion unlikely. The June 2026 Appendix 4C showed about 3.3 quarters of funding.
  • Dilution. Shares grew from about 163.6m (restated, 1 July 2024) to 209.0m (30 June 2026). Further equity raises at depressed prices are likely.
  • Fast-follower 510(k) competitors using PainChek's De Novo as predicate, potentially including EHR partners such as PointClickCare.
  • Reimbursement risk. CMS acceptance of RTM billing for dementia pain assessment is untested; the outcome of the CPT-code request was not disclosed.
  • Key-person and transition risk. The new CEO started in August 2026, and two long-serving directors and the founder-era CEO left within three months.
  • Data privacy and AI regulation of facial analysis in vulnerable populations across the AU, UK, EU (including the AI Act) and US.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 Apr 2025R&D tax refund received; FDA review update; Infant App launch in AustraliaFunding plus the first consumer product
30 Apr 2025March 2025 quarterly 4CRoutine
20 May 2025US Head of Business Development appointedUS go-to-market build
27 May 2025Eldermark partnershipUS/Canada distribution reach
5 Jun 2025"Productive final" FDA De Novo meeting; additional information due end of June; clearance projected mid-to-late September 2025Timeline slippage from the first half of 2025
3 Jul 2025Strong quarterly sales growth reportedContracted licences +10% YoY, implemented +17% YoY
21 Jul 2025Final FDA De Novo submission completedRegulatory milestone
24–28 Jul 2025Trading halt; A$7.5m placement (net licence retention 106%)Funds US entry and Infant marketing
29 Aug 2025FY2025 preliminary result: customer revenue A$3.36m (+26%), net loss A$7.69mGrowth decelerating
17 Sep 2025Compelling clinical and economic results in Scottish pilotUK evidence base
30 Sep 2025FY2025 Annual Report and Corporate Governance StatementRoutine
7–8 Oct 2025Trading halt, then FDA De Novo clearance announced ("US$100M US market")Transformational regulatory milestone; shares peaked about A$0.08 pre-consolidation (about A$0.80 adjusted) on 10 Oct
13 Oct 2025First US customer: Jewish Home FamilyRapid first commercial win
16 Oct 2025Response to ASX Aware LetterContinuous-disclosure query following the FDA announcement period
17 Oct 2025Key hire to drive Infant App ("A$15bn addressable market")Infant commercialisation push
24 Oct 2025Notice of AGM; consolidation proposalCapital structure
31 Oct 2025September 2025 quarter 4C and investor presentationPost-FDA update
26 Nov 2025AGM; 1-for-10 share consolidation completed; LTI and NED rights approvedCapital restructuring
22–30 Dec 2025Director share issues at A$0.34 (Daffas A$50k; Payne A$10k) and quotation of securitiesInsider participation in July placement after shareholder approval
29 Jan 2026Access to US RTM reimbursement announcedNew US revenue model concept
30 Jan 2026Business update: 115k contracted licences; A$5.6m contracted ARR; A$4.0m implemented ARR; A$1.9m ARR pipelinePeak "contracted" framing
27 Feb 2026H1 FY2026: customer revenue A$1.734m (+5%), net loss A$4.70m (+42% vs H1 FY2025)Revenue stall; key inflection
26 Mar 2026"Material sales momentum in UK"UK activations
Mar 2026Planned RTM model launch at HIMSS, Las VegasOutcome not disclosed
14 Apr 2026Sabra MSA for up to 20,000 bedsLargest US channel deal
30 Apr 2026March 2026 quarter 4C: 118,577 contracted licences; A$5.9m contracted ARR; cash A$2.3m; 18.8m assessments; 9-month customer revenue +5.4% to A$2.681mCash tight before refinancing; share fell about 23% on the day
May 2026University of Iowa presents US validation at Argentum, NashvilleUS clinical credibility
22 May 2026A$5.5m convertible notes (12%, A$0.195 conversion, 12-month term)Expensive bridge funding; price fell from A$0.13 toward about A$0.10
25 May 2026Lil Bianchi appointed Non-Executive ChairGovernance refresh
4 Jun 2026First Sabra US care facilities secured (Traditions memory care)First owner-funded deployments
5 Jun 2026Casson Consulting UK ROI study publishedCommercial evidence
1 Jul 2026Infant pharmacy pilot commences in SA; Silverado pilot agreedChannel tests
6 Jul 2026CEO/MD Philip Daffas departs; COO Andy Hoggan interim CEOLeadership reset
8 Jul 2026Major platform enhancement (Dashboard) launched globallyProduct differentiation
20 Jul 2026Karen Holzberger appointed CEO (US$387k)US-centric leadership
22 Jul 2026A$1.123m R&D tax incentive refund receivedLiquidity support
29 Jul 2026June 2026 quarter 4C: implemented ARR A$4.46m (+5.9% QoQ); receipts +27%; KPI redefinitionReporting reset to implemented metrics
28 Aug 2026FY2026 Appendix 4E: loss A$8.94m; going-concern emphasis of matter; first segment noteResults; funding risk flagged
2 Sep 2026Ross Harricks resigns (effective 1 Sep)Board renewal
3 / 8 Sep 2026Lynx Discovery Series investor webinar (Chair and CEO)Investor engagement on US strategy
29 Sep 2026FY2026 Annual Report releasedRoutine
4 Nov 2026 (scheduled)Annual General Meeting; director nominations closed 16 Sep 2026Upcoming catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Customer revenue rose from AUD 1 Mn in FY2022 to AUD 3.7 Mn in FY2026.
PainChek Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Customer revenue122.73.43.7
Subscription revenue———3.13.6
Training and services revenue———0.20.1
Cost of providing services———11.1
Gross profit, company basis———2.42.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. PainChek Limited, Annual Report 2026 (released 29 Sep 2026)
  2. PainChek Limited, Appendix 4E and audited Financial Report FY2026 (28 Aug 2026)
  3. PainChek, June 2026 Quarterly Activities Report and Appendix 4C (29 Jul 2026)
  4. PainChek, Business Update (30 Jan 2026)
  5. PainChek, Half-Year Report H1 FY2026 (27 Feb 2026), via Webull bulletin
  6. PainChek, ASX announcements index
  7. PainChek, CEO appointment (20 Jul 2026): Platform enhancement (8 Jul 2026) · Resignation of NED (2 Sep 2026) · R&D refund (22 Jul 2026) · Investor webinar (3 Sep 2026)
  8. PainChek, Sabra MSA (14 Apr 2026) and initial Sabra facilities (4 Jun 2026), ASX
  9. PainChek, Placement announcement (28 Jul 2025), ASX: FY2025 Preliminary Final Report (29 Aug 2025), ASX · FY2023 Preliminary Report (31 Aug 2023), ASX
  10. US FDA, De Novo DEN240073 classification letter · RegDataLab DEN240073 summary
  11. PainChek "Our Story" and quarterly news updates (painchek.com)
  12. InvestSMART announcement summaries (30 Apr, 22 May, 6 Jul, 29 Jul 2026)
  13. Kalkine Media (Jul 2026): Biotech Daily / Dr Boreham (Nov 2019, Aug 2021, Oct 2025) · FNArena (Sep 2023) · Stockhead (2021, Oct 2025)
  14. FY2017 ePAT Technologies Annual Report (via Aspect Huntley)
  15. Aggregators, flagged where used: StockAnalysis, TipRanks, Simply Wall St, Stockopedia, Craft.co
  16. Clinical: Atee, Hoti, Hughes et al., Frontiers in Aging Neuroscience (2018) · Frontiers in Pain Research (2022) · Dementia Australia · CNN (Feb 2021)
  17. UK ROI study: Casson Consulting / PainChek (5 Jun 2026), via TSA, Care England and Scottish Care

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.